NCT01568775View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

End Stage Renal Disease

Interventions

DRUG

Aliskiren

All patient and subjects received single dose of aliskiren 300 mg in treatment period.

Trial Locations (1)

Unknown

Charité Universitätsmedizin, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY